TickerFacts.

Compare

Arcus Biosciences, Inc. vs Keros Therapeutics, Inc. vs Schrodinger, Inc. vs Akebia Therapeutics, Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearArcus Biosciences, Inc.
RCUS		Keros Therapeutics, Inc.
KROS		Schrodinger, Inc.
SDGR		Akebia Therapeutics, Inc.
AKBA
Year ended2025-12-312025-12-312025-12-312025-12-31
Revenue$247.00M$244.06M$255.87M$236.20M
Revenue growth (YoY)-4.3%n/m+23.3%+47.5%
Gross marginn/an/a55.7%83.3% (computed)
Operating margin-156.3%27.7%-65.2%9.9%
Net margin-142.9%35.7%-40.4%-2.3%
Net income-$353.00M$87.01M-$103.27M-$5.34M
EPS (Diluted)-$3.29$2.30-$1.41-$0.02
Operating cash flow-$482.00M$107.50M$13.90M$67.99M
Free cash flow-$484.00M$105.95M$12.46M$67.70M
Cash & equivalents$222.00M$287.42M$230.52M$184.84M
Total assets$1.14B$338.02M$726.16M$376.56M
Total liabilitiesn/a$34.89M$362.11M$343.95M
Shareholders' equity$631.00M$303.13M$364.05M$32.61M
Return on year-end equity-55.9%28.7%-28.4%-16.4%
Shares outstanding125.30M19.54Mn/a265.42M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearArcus Biosciences, Inc.Keros Therapeutics, Inc.Schrodinger, Inc.Akebia Therapeutics, Inc.
Latest$247.00M
Ended 2025-12-31		$244.06M
Ended 2025-12-31		$255.87M
Ended 2025-12-31		$236.20M
Ended 2025-12-31
1 year earlier$258.00M
Ended 2024-12-31		$3.55M
Ended 2024-12-31		$207.54M
Ended 2024-12-31		$160.18M
Ended 2024-12-31
2 years earlier$117.00M
Ended 2023-12-31		$151.0K
Ended 2023-12-31		$216.67M
Ended 2023-12-31		$194.62M
Ended 2023-12-31
3 years earlier$112.00M
Ended 2022-12-31		$0
Ended 2022-12-31		$180.96M
Ended 2022-12-31		$292.48M
Ended 2022-12-31
4 years earlier$383.00M
Ended 2021-12-31		$20.10M
Ended 2021-12-31		$137.93M
Ended 2021-12-31		$211.65M
Ended 2021-12-31